Related Experiment Video

Updated: Jun 8, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

[Drug discovery sciences in Japan with focus on molecular-targeted drugs]

Koichi Furukawa1, Kazunori Hamamura, Yuki Ohkawa

  • 1Department of Biochemistry II, Nagoya University Graduate School of Medicine, College of Life and Health Sciences.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|October 20, 2010
PubMed

Insights

Molecular-targeted therapy offers potent cancer treatment but can cause side effects. Glycobiology insights may improve drug sensitivity prediction and minimize adverse events in oncology.

Area of Science:

  • Oncology
  • Molecular Biology
  • Glycobiology

Context:

  • Molecular-targeted therapy has emerged as a significant approach in clinical oncology since the early 2000s.
  • Development of drugs targeting key molecules in cancer progression is based on molecular biological analyses.
  • These therapies show efficacy in suppressing tumor growth but can lead to mechanism-based adverse effects.

Purpose:

  • To review the development and application of molecular-targeted therapies in oncology.
  • To explore the potential of glycobiology in advancing molecular-targeted drug development.
  • To address the urgent issues of "on-target" side effects and prediction of drug sensitivity.

Summary:

  • Molecular-targeted therapies, developed since 2000, effectively inhibit cancer cell proliferation, invasion, and metastasis.
  • These targeted drugs, while potent, can induce specific mechanism-based adverse effects.
  • Promising trials in Japan are exploring novel molecular-targeted therapies, with glycobiology offering potential advancements.

Impact:

  • Highlights the need for strategies to predict drug sensitivity and manage "on-target" side effects.
  • Suggests that integrating glycobiology findings could enhance the precision and safety of cancer therapies.
  • Emphasizes the ongoing evolution of cancer treatment through molecular understanding and targeted drug development.

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening08:34

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening

Published on: October 16, 2015

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.